Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385291327> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4385291327 abstract "Abstract Background Kratom has been used for different reasons such as pain, opioid withdrawal, and relaxation. Kratom can cause dependence and overdose, and it’s classified under ‘drugs of concern’ by the US Drug Enforcement Administration. Despite these concerns, kratom is legal in most of the United States and many countries around the world with easy accessibility. Literature searches reveal recommendations to use buprenorphine (or buprenorphine-naloxone), which are medications to treat opioid use disorder, in order to treat patients with kratom use disorder; however, there are no formal guidelines available. Buprenorphine (or buprenorphine-naloxone) induction is recommended to be conducted under observation (i.e. in the clinic) in the United States, but COVID-19 has resulted in shifts toward telehealth. Objectives Describe case series of successful management of kratom use disorder using telehealth followed by unobserved buprenorphine-naloxone home induction and highlight implications for future management, including maintenance dosage and induction method. Methods We present 2 very similar kratom use disorder patients who reported taking 35 g of kratom per day who underwent unobserved buprenorphine-naloxone home induction. Results Both were seen via telehealth initially. They reported no adverse effects before, during, or after the unobserved home induction on buprenorphine-naloxone but stabilized on significantly different dosages. Conclusion Telehealth followed by unobserved buprenorphine-naloxone induction at home may be an alternative to traditional buprenorphine-naloxone induction where treatment accessibility is limited. In addition to daily doses of kratom use, other factors, such as duration of kratom use and individual psychological factors may determine the most comfortable dose of buprenorphine-naloxone." @default.
- W4385291327 created "2023-07-27" @default.
- W4385291327 creator A5013418645 @default.
- W4385291327 creator A5065921116 @default.
- W4385291327 creator A5081250787 @default.
- W4385291327 creator A5085895098 @default.
- W4385291327 date "2023-07-27" @default.
- W4385291327 modified "2023-10-03" @default.
- W4385291327 title "Kratom use disorder: case reports on successful treatment with home induction of buprenorphine-naloxone" @default.
- W4385291327 cites W2066166905 @default.
- W4385291327 cites W2173132441 @default.
- W4385291327 cites W2791195333 @default.
- W4385291327 cites W2801723370 @default.
- W4385291327 cites W2888368192 @default.
- W4385291327 cites W2938632596 @default.
- W4385291327 cites W2972751004 @default.
- W4385291327 cites W3081825632 @default.
- W4385291327 cites W3128275005 @default.
- W4385291327 cites W4214826883 @default.
- W4385291327 doi "https://doi.org/10.1093/fampra/cmad081" @default.
- W4385291327 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37499179" @default.
- W4385291327 hasPublicationYear "2023" @default.
- W4385291327 type Work @default.
- W4385291327 citedByCount "1" @default.
- W4385291327 countsByYear W43852913272023 @default.
- W4385291327 crossrefType "journal-article" @default.
- W4385291327 hasAuthorship W4385291327A5013418645 @default.
- W4385291327 hasAuthorship W4385291327A5065921116 @default.
- W4385291327 hasAuthorship W4385291327A5081250787 @default.
- W4385291327 hasAuthorship W4385291327A5085895098 @default.
- W4385291327 hasConcept C126322002 @default.
- W4385291327 hasConcept C160735492 @default.
- W4385291327 hasConcept C162324750 @default.
- W4385291327 hasConcept C170493617 @default.
- W4385291327 hasConcept C194828623 @default.
- W4385291327 hasConcept C2778750930 @default.
- W4385291327 hasConcept C2778949969 @default.
- W4385291327 hasConcept C2779418921 @default.
- W4385291327 hasConcept C2779891985 @default.
- W4385291327 hasConcept C2781050511 @default.
- W4385291327 hasConcept C2781063702 @default.
- W4385291327 hasConcept C42219234 @default.
- W4385291327 hasConcept C50522688 @default.
- W4385291327 hasConcept C71924100 @default.
- W4385291327 hasConceptScore W4385291327C126322002 @default.
- W4385291327 hasConceptScore W4385291327C160735492 @default.
- W4385291327 hasConceptScore W4385291327C162324750 @default.
- W4385291327 hasConceptScore W4385291327C170493617 @default.
- W4385291327 hasConceptScore W4385291327C194828623 @default.
- W4385291327 hasConceptScore W4385291327C2778750930 @default.
- W4385291327 hasConceptScore W4385291327C2778949969 @default.
- W4385291327 hasConceptScore W4385291327C2779418921 @default.
- W4385291327 hasConceptScore W4385291327C2779891985 @default.
- W4385291327 hasConceptScore W4385291327C2781050511 @default.
- W4385291327 hasConceptScore W4385291327C2781063702 @default.
- W4385291327 hasConceptScore W4385291327C42219234 @default.
- W4385291327 hasConceptScore W4385291327C50522688 @default.
- W4385291327 hasConceptScore W4385291327C71924100 @default.
- W4385291327 hasLocation W43852913271 @default.
- W4385291327 hasLocation W43852913272 @default.
- W4385291327 hasOpenAccess W4385291327 @default.
- W4385291327 hasPrimaryLocation W43852913271 @default.
- W4385291327 hasRelatedWork W1975094265 @default.
- W4385291327 hasRelatedWork W2555959925 @default.
- W4385291327 hasRelatedWork W2755304799 @default.
- W4385291327 hasRelatedWork W2800254292 @default.
- W4385291327 hasRelatedWork W2987196569 @default.
- W4385291327 hasRelatedWork W3013655406 @default.
- W4385291327 hasRelatedWork W3026250625 @default.
- W4385291327 hasRelatedWork W3129170610 @default.
- W4385291327 hasRelatedWork W3160430790 @default.
- W4385291327 hasRelatedWork W4223945972 @default.
- W4385291327 isParatext "false" @default.
- W4385291327 isRetracted "false" @default.
- W4385291327 workType "article" @default.